Press releases
* (R) = Regulatory press releases
Nov 7, 2022
(R) Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy
Oct 28, 2022
Invitation to presentation of Cantargia’s report for the third quarter of 2022 on November 10 at 3.00 p.m. CET
Oct 14, 2022
(R) Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
Sep 22, 2022
(R) Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy
Sep 15, 2022
(R) Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
Aug 31, 2022
(R) New number of shares and votes in Cantargia
Aug 30, 2022
Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy
Aug 30, 2022
